BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

3518

500420

TORNTPHARM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

TORRENT PHARMACEUTICALS L performance

Today’s low

Today’s high

₹ 3287.10 ₹ 3360.00
₹ 3322.00

52 week low

52 week high

₹ 2519.95 ₹ 3590.70
₹ 3322.00

Open Price

₹ 3322.70

Prev. Close

₹ 3322.70

Volume (Shares)

1148944.00

Total traded value

₹ 38167.91

Upper Circuit

₹ 3654.90

Lower Circuit

₹ 2990.50

info

TORRENT PHARMACEUTICALS L Share Price Update

As of the latest trading session, TORRENT PHARMACEUTICALS L share price is currently at ₹ 3322, which is down by ₹ -0.69 from its previous closing. Today, the stock has fluctuated between ₹ 3287.10 and ₹ 3360.00. Over the past year, TORRENT PHARMACEUTICALS L has achieved a return of 25.71 %. In the last month alone, the return has been 4.33 %. Read More...

TORRENT PHARMACEUTICALS L fundamentals


  • Market cap (Cr)

    1,12,431.60

  • P/E Ratio (TTM)

    61.49

  • Beta

    0.49

  • Book Value / share

    222.38

  • Return on equity

    20.43%

  • EPS (TTM)

    53.90

  • Dividend yield

    0.84%

  • Net profit/quarter (Cr)

    485.00

info icon alternate text
  • Market cap (Cr)

    1,11,957.80

  • P/E Ratio (TTM)

    61.49

  • Beta

    0.45

  • Book Value / share

    222.38

  • Return on equity

    20.43%

  • EPS (TTM)

    53.90

  • Dividend yield

    0.84%

  • Net profit/quarter (Cr)

    485.00

info icon alternate text

TORRENT PHARMACEUTICALS L Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 2330.00
Operating Expense 1729.00
Net Profit 485.00
Net Profit Margin (%) 20.81
Earnings Per Share (EPS) 14.33
EBITDA 890.00
Effective Tax Rate (%) 25.49
Particulars SEP 2024 (Values in Cr)
Revenue 2376.00
Operating Expense 1757.00
Net Profit 460.00
Net Profit Margin (%) 19.36
Earnings Per Share (EPS) 13.60
EBITDA 914.00
Effective Tax Rate (%) 31.34
Particulars JUN 2024 (Values in Cr)
Revenue 2394.00
Operating Expense 1792.00
Net Profit 469.00
Net Profit Margin (%) 19.59
Earnings Per Share (EPS) 13.86
EBITDA 920.00
Effective Tax Rate (%) 29.68
Particulars MAR 2024 (Values in Cr)
Revenue 2094.00
Operating Expense 1689.00
Net Profit 410.00
Net Profit Margin (%) 19.57
Earnings Per Share (EPS) 12.12
EBITDA 792.00
Effective Tax Rate (%) 22.64
Particulars DEC 2023 (Values in Cr)
Revenue 2083.00
Operating Expense 1682.00
Net Profit 297.00
Net Profit Margin (%) 14.25
Earnings Per Share (EPS) 8.78
EBITDA 690.00
Effective Tax Rate (%) 30.93
Particulars MAR 2024 (Values in Cr)
Revenue 8370.00
Operating Expense 6707.00
Net Profit 1357.00
Net Profit Margin (%) 16.21
Earnings Per Share (EPS) 40.10
EBITDA 2981.00
Effective Tax Rate (%) 29.21
Particulars MAR 2023 (Values in Cr)
Revenue 7547.00
Operating Expense 6200.00
Net Profit 1052.00
Net Profit Margin (%) 13.93
Earnings Per Share (EPS) 31.07
EBITDA 2547.00
Effective Tax Rate (%) 33.29
Particulars MAR 2022 (Values in Cr)
Revenue 6666.00
Operating Expense 5480.00
Net Profit 991.00
Net Profit Margin (%) 14.86
Earnings Per Share (EPS) 58.59
EBITDA 2304.00
Effective Tax Rate (%) 32.40
Particulars MAR 2021 (Values in Cr)
Revenue 6333.00
Operating Expense 5203.00
Net Profit 1138.00
Net Profit Margin (%) 17.96
Earnings Per Share (EPS) 67.24
EBITDA 2315.00
Effective Tax Rate (%) 16.69
Particulars MAR 2020 (Values in Cr)
Revenue 6026.00
Operating Expense 5288.00
Net Profit 939.00
Net Profit Margin (%) 15.58
Earnings Per Share (EPS) 55.46
EBITDA 2154.00
Effective Tax Rate (%) 15.93
Particulars MAR 2024 (Values in Cr)
Book Value / Share 202.57
ROE % 25.38
ROCE % 23.21
Total Debt to Total Equity 0.72
EBITDA Margin 32.76
Particulars MAR 2023 (Values in Cr)
Book Value / Share 183.13
ROE % 20.50
ROCE % 19.48
Total Debt to Total Equity 0.78
EBITDA Margin 30.01
Particulars MAR 2022 (Values in Cr)
Book Value / Share 351.75
ROE % 18.26
ROCE % 18.20
Total Debt to Total Equity 0.76
EBITDA Margin 30.77
Particulars MAR 2021 (Values in Cr)
Book Value / Share 344.90
ROE % 23.49
ROCE % 16.96
Total Debt to Total Equity 1.00
EBITDA Margin 31.69
Particulars MAR 2020 (Values in Cr)
Book Value / Share 284.99
ROE % 21.47
ROCE % 14.79
Total Debt to Total Equity 1.24
EBITDA Margin 28.86
Particulars MAR 2024 (Values in Cr)
Book Value / Share 201.76
ROE % 20.43
ROCE % 20.40
Total Debt to Total Equity 0.60
EBITDA Margin 34.93
Particulars MAR 2023 (Values in Cr)
Book Value / Share 190.75
ROE % 16.43
ROCE % 17.68
Total Debt to Total Equity 0.62
EBITDA Margin 33.10
Particulars MAR 2022 (Values in Cr)
Book Value / Share 374.94
ROE % 16.02
ROCE % 16.57
Total Debt to Total Equity 0.63
EBITDA Margin 34.19
Particulars MAR 2021 (Values in Cr)
Book Value / Share 356.30
ROE % 20.41
ROCE % 15.96
Total Debt to Total Equity 0.87
EBITDA Margin 35.81
Particulars MAR 2020 (Values in Cr)
Book Value / Share 302.59
ROE % 18.52
ROCE % 14.41
Total Debt to Total Equity 1.08
EBITDA Margin 34.92
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 839.04
Total Assets 15060.58
Total Liabilities 15060.58
Total Equity 6856.15
Share Outstanding 338445440
Price to Book Ratio 12.89
Return on Assets (%) 10.99
Return on Capital (%) 15.35
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 571.46
Total Assets 15011.85
Total Liabilities 15011.85
Total Equity 6198.07
Share Outstanding 338445440
Price to Book Ratio 8.06
Return on Assets (%) 8.29
Return on Capital (%) 10.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 403.41
Total Assets 13099.84
Total Liabilities 13099.84
Total Equity 5952.95
Share Outstanding 169222720
Price to Book Ratio 7.46
Return on Assets (%) 5.93
Return on Capital (%) 7.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 603.50
Total Assets 14074.65
Total Liabilities 14074.65
Total Equity 5837.17
Share Outstanding 169222720
Price to Book Ratio 7.13
Return on Assets (%) 8.89
Return on Capital (%) 11.74
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 666.65
Total Assets 14009.74
Total Liabilities 14009.74
Total Equity 4823.22
Share Outstanding 169222720
Price to Book Ratio 6.52
Return on Assets (%) 7.31
Return on Capital (%) 11.15
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 108.76
Total Assets 12376.59
Total Liabilities 12376.59
Total Equity 6828.76
Share Outstanding 338445440
Price to Book Ratio 12.89
Return on Assets (%) 10.96
Return on Capital (%) 13.35
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 147.61
Total Assets 12871.93
Total Liabilities 12871.93
Total Equity 6455.96
Share Outstanding 338445440
Price to Book Ratio 8.06
Return on Assets (%) 8.16
Return on Capital (%) 9.54
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 69.46
Total Assets 11152.56
Total Liabilities 11152.56
Total Equity 6345.42
Share Outstanding 169222720
Price to Book Ratio 7.46
Return on Assets (%) 8.88
Return on Capital (%) 10.23
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 66.42
Total Assets 11761.04
Total Liabilities 11761.04
Total Equity 6030.10
Share Outstanding 169222720
Price to Book Ratio 7.13
Return on Assets (%) 9.67
Return on Capital (%) 10.93
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 390.95
Total Assets 11884.47
Total Liabilities 11884.47
Total Equity 5120.97
Share Outstanding 169222720
Price to Book Ratio 6.52
Return on Assets (%) 7.89
Return on Capital (%) 10.39
Particulars MAR 2024 (Values in Cr)
Net Income 2352.11
Cash from Operations 3764.18
Cash from Investing -167.90
Cash from Financing -2779.64
Net change in Cash 318.54
Free Cash Flow 4196.96
Particulars MAR 2023 (Values in Cr)
Net Income 1847.16
Cash from Operations 2766.20
Cash from Investing -2415.31
Cash from Financing 77.36
Net change in Cash 30.18
Free Cash Flow 3340.14
Particulars MAR 2022 (Values in Cr)
Net Income 1225.91
Cash from Operations 2224.01
Cash from Investing -196.63
Cash from Financing -1781.05
Net change in Cash -174.69
Free Cash Flow 2426.58
Particulars MAR 2021 (Values in Cr)
Net Income 1526.26
Cash from Operations 2180.85
Cash from Investing -449.42
Cash from Financing -1650.79
Net change in Cash -94.86
Free Cash Flow 2516.00
Particulars MAR 2020 (Values in Cr)
Net Income 1186.57
Cash from Operations 1676.95
Cash from Investing 198.61
Cash from Financing -1549.04
Net change in Cash 42.48
Free Cash Flow 2083.73
Particulars MAR 2024 (Values in Cr)
Net Income 1916.57
Cash from Operations 3217.78
Cash from Investing -296.07
Cash from Financing -2577.57
Net change in Cash 19.46
Free Cash Flow 3562.12
Particulars MAR 2023 (Values in Cr)
Net Income 1577.02
Cash from Operations 2537.87
Cash from Investing -2384.07
Cash from Financing 80.74
Net change in Cash -37.92
Free Cash Flow 3108.77
Particulars MAR 2022 (Values in Cr)
Net Income 1466.21
Cash from Operations 2380.37
Cash from Investing -159.70
Cash from Financing -1977.27
Net change in Cash 3.13
Free Cash Flow 2488.54
Particulars MAR 2021 (Values in Cr)
Net Income 1366.11
Cash from Operations 1782.79
Cash from Investing -316.28
Cash from Financing -1581.20
Net change in Cash -324.59
Free Cash Flow 1984.78
Particulars MAR 2020 (Values in Cr)
Net Income 1116.77
Cash from Operations 1786.60
Cash from Investing 269.43
Cash from Financing -1555.48
Net change in Cash 293.85
Free Cash Flow 2132.79
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High

TORRENT PHARMACEUTICALS L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
3322.00 -0.02 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 3308.80
  • 26 Days 3239.10
  • 10 Days 3287.40
  • 50 Days 3211.80
  • 12 Days 3279.90
  • 100 Days 3207.60
  • 20 Days 3254.00
  • 200 Days 3130.10
3327.03 PIVOT

First Support

3302.67

First Resistance

3347.07

Second Support

3282.63

Second Resistance

3371.43

Third Support

3258.27

Third Resistance

3391.47

RSI

58.73

ADX

15.55

MACD

40.75

Williams % R

-15.04

Commodity Channel Index (CCI)

126.12

Date

2025-04-30

Week

321776.00

Same Day

994955.00

Month

274025.00

1 Year

0.49

3 Year

0.47

Over 1 Month

4.33%

down

Over 1 Year

25.71%

down

Over 3 Months

-1.07%

down

Over 3 Years

33.49%

down

Over 6 Months

5.87%

down

Over 5 Years

23.15%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

TORRENT PHARMACEUTICALS L shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
7.03%
Promoter Holdings
68.3%
FII
16.31%
DII
8.34%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Torrent Investments Limited (formerly Known As Torrent Investments Private Limited) 2.311834E8 (68.31%) Shareholding of Promoter and Promoter Group
Nps Trust 6099267.0 (1.8%) Public Shareholding
Mehta Family Trust 4 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mehta Family Trust 3 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mehta Family Trust 2 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mehta Family Trust 1 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aman Mehta 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Shaan Mehta 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Varun Sudhir Mehta 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Jinal Sudhir Mehta 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Sapna Samir Mehta 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Anita Sudhir Mehta 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Samir Uttamlal Mehta 400.0 (0.0%) Shareholding of Promoter and Promoter Group
Sudhir Uttamlal Mehta 400.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

TORRENT PHARMACEUTICALS L corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
12 Feb 2024 22.0 Interim 12 Feb 2024 Equity shares
23 Jun 2023 8.0 Final 23 Jun 2023 Equity shares
03 Feb 2023 14.0 Interim 03 Feb 2023 Equity shares
03 Jun 2022 15.0 Special 06 Jun 2022 Equity shares
03 Jun 2022 8.0 Final 06 Jun 2022 Equity shares
02 Feb 2022 25.0 Interim 03 Feb 2022 Equity shares
17 Jun 2021 15.0 Final 18 Jun 2021 Equity shares
15 Feb 2021 20.0 Interim 16 Feb 2021 Equity shares
18 Mar 2020 17.0 Interim 19 Mar 2020 Equity shares
18 Mar 2020 15.0 Special 19 Mar 2020 Equity shares
13 Jun 2019 4.0 Final 14 Jun 2019 Equity shares
06 Feb 2019 13.0 Interim 07 Feb 2019 Equity shares
18 Jun 2018 5.0 Final 20 Jun 2018 Equity shares
15 Feb 2018 9.0 Interim 19 Feb 2018 Equity shares
19 Jun 2017 4.0 Final 21 Jun 2017 Equity shares
10 Feb 2017 10.0 Interim 13 Feb 2017 Equity shares
16 Mar 2016 15.0 Interim 2 17 Mar 2016 Equity shares
11 Feb 2016 20.0 Interim 12 Feb 2016 Equity shares
15 Jun 2015 6.25 Final 17 Jun 2015 Equity shares
02 Feb 2015 5.0 Interim 03 Feb 2015 Equity shares
16 Jun 2014 5.0 Final 18 Jun 2014 Equity shares
24 Jan 2014 5.0 Interim 27 Jan 2014 Equity shares
10 Jun 2013 7.0 Final 12 Jun 2013 Equity shares
10 Jun 2013 10.0 Special 12 Jun 2013 Equity shares
01 Feb 2013 6.0 Interim 04 Feb 2013 Equity shares
11 Jun 2012 2.5 Final 13 Jun 2012 Equity shares
27 Jan 2012 6.0 Interim 30 Jan 2012 Equity shares
06 Jun 2011 2.0 Special 08 Jun 2011 Equity shares
06 Jun 2011 6.0 Final 08 Jun 2011 Equity shares
04 Jun 2010 6.0 Final 08 Jun 2010 Equity shares
08 Jun 2009 4.0 Final 10 Jun 2009 Equity shares
19 Jun 2008 3.5 Final 23 Jun 2008 Equity shares
23 Mar 2007 3.0 Interim 26 Mar 2007 Equity shares
15 Jun 2006 0.0 Final 01 Jan 0001 Equity shares
09 Jun 2005 0.0 Final 13 Jun 2005 Equity shares
Ex-Date Ex-Bonus Ratio
11 Jul 2022 08 Jul 2022 1:1
24 Jul 2013 23 Jul 2013 1:1
27 Feb 2006 20 Feb 2006 1:1
Ex-Date Old FV NEW FV Record Date
20 Feb 2006 10.0 5.0 27 Feb 2006
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Jun 2024 6.0 Final 21 Jun 2024 Equity shares
12 Feb 2024 22.0 Interim 12 Feb 2024 Equity shares
23 Jun 2023 8.0 Final 23 Jun 2023 Equity shares
03 Feb 2023 14.0 Interim 03 Feb 2023 Equity shares
03 Jun 2022 15.0 Special 06 Jun 2022 Equity shares
03 Jun 2022 8.0 Final 06 Jun 2022 Equity shares
02 Feb 2022 25.0 Interim 03 Feb 2022 Equity shares
17 Jun 2021 15.0 Final 18 Jun 2021 Equity shares
15 Feb 2021 20.0 Interim 16 Feb 2021 Equity shares
18 Mar 2020 17.0 Interim 19 Mar 2020 Equity shares
18 Mar 2020 15.0 Special 19 Mar 2020 Equity shares
13 Jun 2019 4.0 Final 14 Jun 2019 Equity shares
06 Feb 2019 13.0 Interim 07 Feb 2019 Equity shares
18 Jun 2018 5.0 Final 20 Jun 2018 Equity shares
15 Feb 2018 9.0 Interim 19 Feb 2018 Equity shares
19 Jun 2017 4.0 Final 21 Jun 2017 Equity shares
10 Feb 2017 10.0 Interim 13 Feb 2017 Equity shares
16 Mar 2016 15.0 Interim 2 17 Mar 2016 Equity shares
11 Feb 2016 20.0 Interim 12 Feb 2016 Equity shares
15 Jun 2015 6.25 Final 17 Jun 2015 Equity shares
02 Feb 2015 5.0 Interim 03 Feb 2015 Equity shares
16 Jun 2014 5.0 Final 18 Jun 2014 Equity shares
24 Jan 2014 5.0 Interim 27 Jan 2014 Equity shares
10 Jun 2013 7.0 Final 12 Jun 2013 Equity shares
10 Jun 2013 10.0 Special 12 Jun 2013 Equity shares
01 Feb 2013 6.0 Interim 04 Feb 2013 Equity shares
11 Jun 2012 2.5 Final 13 Jun 2012 Equity shares
27 Jan 2012 6.0 Interim 30 Jan 2012 Equity shares
06 Jun 2011 2.0 Special 08 Jun 2011 Equity shares
06 Jun 2011 6.0 Final 08 Jun 2011 Equity shares
04 Jun 2010 6.0 Final 08 Jun 2010 Equity shares
08 Jun 2009 4.0 Final 10 Jun 2009 Equity shares
19 Jun 2008 3.5 Final 23 Jun 2008 Equity shares
23 Mar 2007 3.0 Interim 26 Mar 2007 Equity shares
15 Jun 2006 0.0 Final 01 Jan 0001 Equity shares
09 Jun 2005 0.0 Final 13 Jun 2005 Equity shares
Ex-Date Ex-Bonus Ratio
11 Jul 2022 08 Jul 2022 1:1
24 Jul 2013 23 Jul 2013 1:1
27 Feb 2006 20 Feb 2006 1:1
Ex-Date Old FV NEW FV Record Date
20 Feb 2006 10.0 5.0 27 Feb 2006

TORRENT PHARMACEUTICALS L Share Price

Torrent Pharmaceuticals Limited is a leading player in the Indian pharmaceutical sector, concentrating on the chronic and sub-chronic therapeutic segments. The Company has established itself as a leader in developing niche pharmaceutical solutions through its patient-centric innovation. The Company is a dominant player in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Vitamins and Nutrients (VMN), Gastro-Intestinal (GI) and Anti-Diabetes (AD) therapies in India. It has a strong international presence across more than 40 countries with operations in regulated and emerging markets, such as the US, Europe, Germany, Brazil and Rest of the World.

The Company operates through its wholly-owned subsidiaries spread across 12 countries with major setups in the US, Germany and Brazil. Apart from this, it has a modern and well-equipped state-of-the-art R&D Centre at Bhat near Ahmedabad, built with an investment of US $ 40 million.

Torrent Pharmaceuticals Limited was founded in 1959 as Trinity Laboratories by Late Shri U. N. Mehta. Trinity was later renamed as Torrent Pharmaceuticals Limited and taken public in July 15th, 1972. In 1980, Company started their first manufacturing facility at Vatva and received first export order in year 1983. In year 1986, it started second manufacturing plant at Chhatral. In the year 1995, Torrent Gujarat Biotech Ltd plant was commissioned.

In the year 1996, the company acquired the Pharma related investments and business of Torrent Exports Ltd and also commissioned the state-of-the-art R&D centre. In the year 1997, India Infusions Ltd was merged with the company. As a part of restructuring, the company formed three new divisions namely, Prima, Vista and Psycan in the year 1999.

During the year 2001-02, the company launched 31 new products, out of which 8 were first time launches in India. The company completed the upgradation and modernization programme for the formulations plant at the total cost of Rs 48 crore. Also, they acquired a small pharmaceutical company, namely Fornex Industrial Farmaceutica Ltda, later renamed as Torrent Do Brasil Ltda, in Brazil for Rs 128 lakh.

During the year, the company divested their entire 50% equity stake in Sanofi Torrent (India) Ltd to their joint venture partner Sanofi Synthelabo, France. Also, they transferred their entire equity holding of 1,95,04,691 shares in the sick industrial undertaking Torrent Gujarat Biotech Ltd to Torrent Pvt Ltd, a company belonging to the promoter group.

During the year 2002-03, the company introduced 28 new products including the line extensions. The company completed the upgradation of bulk drug plant during the year, which was started during the financial year 2001-02. Also, the company incorporated Torrent Pharma GmbH as a wholly owned subsidiary company in Germany.

During the year 2003-04, the company set up a wholly owned subsidiary company, namely Torrent Pharma Inc in USA with the objective of business development in the large, growing and highly profitable North America generic market. Also, they introduced 25 new products during the year.

Torrent Pharma's presence in Germany started with the acquisition of Heumann Pharma from Pfizer in 2004-05. The Company entered into a License Agreement with Novartis granting global rights for further development and commercialization of its patented AGE Breaker Compound to Novartis. Also, they signed research collaboration agreement with AstraZeneca, another leading global pharmaceuticals company with the aim of discovering a novel drug candidate for the treatment of hypertension. The company incorporated Torrent Pharma Philippines Inc as a wholly owned subsidiary in the Philippines, with a view to tap the huge potential in Philippines.

During the year 2005-06, the company successfully completed capacity expansion and consolidation of bulk drug plant at manufacturing unit in Indrad. The company entered into an agreement with Novo Nordisk India Pvt Ltd, a wholly owned subsidiary of Novo Nordisk A/S, Denmark to extend existing contract manufacturing arrangement for manufacture of Human Insulin formulations.

During the year, the company introduced 43 new products in the market. Also, the company launched new divisions AXON and NEURON and expanded their field force in order to tap increasing business opportunities in CNS segment. In April 2006, they launched a new division 'PSYCAN AZUCA' to exclusively cater to the needs of the significant and growing diabetes population in the country.

During the year, the company acquired Heumann Pharma GmbH & Co Generica KG (Heumann) of Germany for a cash consideration of euro 3.31 million (Rs.17.20 crores). Heumann, is engaged in the business of marketing generic medicines in Germany under the brand name 'Heumann'. In March 2006, the company incorporated Laboratorios Torrent SA de CV to seek registrations of their products in Mexico and subsequently launch a basket of products in the cardiovascular, central nervous system and oral anti-diabetes area. In April 2006, the company incorporated Torrent Pharma Japan Co Ltd as a wholly owned subsidiary in Japan, to cover the generic market in the country effectively for future business prospects.

During the year 2006-07, the company launched 49 new products in the market. The manufacturing facilities at Chatral received approval from the US Food and Drug Administration for the API (active pharmaceutical ingredient) and oral solid dosage formulations facilities. The company initiated process of setting up of a new Greenfield manufacturing site in the state of Sikkim to support the growth in domestic market. Also, the company incorporated a subsidiary in Mexico, named Laboratorios Torrent SA de CV, as a first step for entry into the lucrative Mexican market.

During the year 2007-08, the company launched 52 new products in the market. They successfully entered the highly competitive US market with launch of Citalopram. During the year, the company undertook capacity expansion of 30% in tablet formulations at Baddi plant and the project is nearing completion. They also completed development for nine molecules for the European Union market and nine molecules for United States market.

During the year 2008-09, the company made an investment of Rs 2.05 crore in the equity shares of their wholly owned subsidiary Laboratories Torrent, SA De CV, in Mexico. In September 2008, the company received the US Food and Drug Administration approval for anti-hypertension drug amlodipine besylate tablets in multiple strengths and in November 2008, their generic, risperidone, in tablet forms of various strengths, also got the approval.

In 2009, Torrent Pharmaceuticals commissioned a dedicated formulation and packaging unit for manufacturing insulin exclusively for Novo Nordisk. During the year under review, the company entered into license and supply agreement with AstraZeneca for marketing its products in international market.In 2010, Torrent Pharmaceuticals' Baddi plant received OHAS Audit 18001:2007certification. During the year under review, the Baddi facility was approved by the regulatory authority of Uganda. During the year under review, Torrent Pharmaceuticals forayed into the therapeutic areas of gynaecology and oncology. During the year under review, Torrent Pharmaceuticals commissioned a subsidiary in United Kingdom and Romania. During the year under review, Torrent Research Center developed Long Acting Injectables technology.

In 2011, Torrent Pharmaceuticals' Sikkim plant commenced operation. During the year under review, Torrent Research Center developed indigenous Nasal Drug Delivery system. During the year under review, Torrent Pharmaceuticals set up Sparsh, a dedicated division to cater to Dermatology segment.

In 2013, Torrent Pharmaceuticals entered into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab.

In 2014, Torrent Pharmaceuticals acquired Elder Pharma's identified Indian branded formulation business in India and Nepal. During the year under review, the company launched Nephro, a dedicated division to cater to the Nephrology segment. During the year under review, Torrent Pharmaceuticals' Dahej plant commenced operations.

In 2015, Torrent Pharmaceuticals acquired 100% stake of Zyg Pharma, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions. In 2016, Torrent Pharmaceuticals' Dahej plant received USFDA approval. During the year under review, the company acquired API manufacturing unit of Hyderabad based Glochem Industries Limited.

In 2017, Torrent Pharmaceuticals acquired Unichem's domestic and Nepal business and also its Sikkim manufacturing facility. During the year under review, the company acquired women healthcare brands from Novartis.

In 2018, Torrent Pharmaceuticals acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.

As of 31st March, 2019, the Company has 16 subsidiaries, out of which 4 are step down subsidiaries. Bio-Pharm Inc., a wholly owned subsidiary of Torrent Pharma Inc. USA ('TPI') merged with TPI with effect from 1st January, 2019. The merger aims at administrative convenience and to achieve higher operational efficiencies.

As of 31st March, 2020, the Company has 15 subsidiaries, out of which 3 are step down subsidiaries. Aptil Pharma Limited, a wholly owned subsidiary of Torrent Pharma (UK) Limited., UK dissolved w.e.f. 15th October, 2019 and consequently, the business of Aptil was merged into Torrent Pharma (UK) Limited.

During year 2021, Company launched Dapagliflozin & Rivaroxaban in the Cardiovascular therapy, Brivaracetam in the Central Nervous System therapy, Obeticholic Acid within the Gastro Intestinal therapy and NDDS Tapentadol Nasal spray in Pain Analgesic therapy.

During the year 2021-22 , TPL (Malta) Limited, wholly owned subsidiary of the Company and Torrent Pharma (Malta) Limited wholly owned subsidiary of TPL (Malta) Limited were incorporated on 17th August, 2021.

During the year 2022-23, the Company acquired 100% of the equity shares of Curatio Health Care (I) Private Limited (CHPL) and its two wholly owned subsidiaries, at Philippines and Sri Lanka for a total consideration costing Rs. 2000 Crores. Accordingly, Curatio Health Care (I) Private Limited (CHPL) was amalgamated with the Parent Company effective from 14th October, 2022, the Appointed Date.

The Company launched 6 products in the CNS, diabetic and cardio segments with Rivaroxaban and Desvenlafaxine being the two biggest success in 2023.

In 2024, Company launched its first oncology product in the US market from its new Bileshwarpura facility and commenced commerical operations. It entered into strategic alliance with Zydus Lifesciences Ltd to strengthen the gastroenterology portfolio while addressing the growing patients' needs in NASH & NAFLD. The Company has strategically diversified and strengthened its presence in some of the key therapies linked to patent expiries like Sitagliptin and its Fixed Dose Combinations (FDC), Linagliptin and its FDC in the anti-diabetic segment, Ferric Carboxy Maltose in gynecology therapy and Lasmitidan in the CNS segment. Further, it has entered high potential market of Sodium Alginate, Imeglimin, Brivaracetam SR and Digestive Enzyme market to cater to unmet therapy needs and launched several brand extensions.

Parent organization Torrent
NSE symbol TORNTPHARM
Founded 1972
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Torrent Pharmaceuticals Ltd?

Answer Field

The share price of Torrent Pharmaceuticals Ltd for NSE is ₹ 3322 and for BSE is ₹ 3308.

What is the Market Cap of Torrent Pharmaceuticals Ltd?

Answer Field

The market cap of Torrent Pharmaceuticals Ltd for NSE is ₹ 11,24,31.60 Cr. and for BSE is ₹ 11,19,57.80 Cr. as of now.

What is the 52 Week High and Low of Torrent Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Torrent Pharmaceuticals Ltd for NSE is ₹ 3590.70 and ₹ 2519.95 and for BSE is ₹ 3589.95 and ₹ 2513.05.

How to Buy Torrent Pharmaceuticals Ltd share?

Answer Field

You can trade in Torrent Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Torrent Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 25.71%.

What is the Current Share Price of Torrent Pharmaceuticals Ltd?

Answer Field

Torrent Pharmaceuticals Ltd share price is for NSE ₹ 3322 & for BSE ₹ 3308 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Torrent Pharmaceuticals Ltd Share?

Answer Field

The market cap of Torrent Pharmaceuticals Ltd for NSE ₹ 11,24,31.60 & for BSE ₹ 11,19,57.80 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Torrent Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Torrent Pharmaceuticals Ltd share is 61.49.

What is the PB ratio of Torrent Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Torrent Pharmaceuticals Ltd share is 222.38.

How to Buy Torrent Pharmaceuticals Ltd Share?

Answer Field

You can trade in Torrent Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Torrent Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Torrent Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Torrent Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|